Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Tear Sheet: CohBar Inc. ($CWBR)

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for ourĀ Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Visit his Stock Gumshoe page for more.] Bacteria are prokaryotes. Animal cells, fungi and plants are eukaryotes. Prokaryotes tend to be acellular and […]

Cisco, Chang & Charlie Part 3

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

Oncotutorial

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Long Idea of the Year

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

Quickster: Update on Corbus

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

The 12 Biotechs of Christmas: Six

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

The 12 Biotechs of Christmas: Five

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

The 12 Biotechs of Christmas: Four

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

The Twelve Biotechs of Christmas: Two

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

Recent Author Comments

On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Allison....nice find, but let me be the first to assert it has NO chance of success. This is neurological magical thinking at its most execrable. When I have more time I will explain the reasoning, threadbare though it is, but seriously this is high sillin[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Yes, it's a prevalent notion.....diminished fecal biome diversity, as can be driven by antibiotics, is strongly linked to weight gain and probably causes MUCH human obesity.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
They ARE the playing field my dear Cleveland! And have a grreat Thanksgiving pal!!!![...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Thanks lane. Bit of a surprise. At the San Diego meeting, CEO Allen told me they were good to go in terms of capital til 4Q18. They may intend expanding their preclinical efforts because they possess many MDP's that need characterizing or screening for cli[...]
On Microblog: PRE and AFTER Market Discussion Thread ( $XYZ or #Subject REQIUIRED in EACH post, TIA )
This was not cleared with me and I vastly prefer ALL biotech discussion be confined to the main thread. People have already demonstrated confusion when there are two main discussion threads. Having yet another is courting catastrophe and chaos. If you have[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Their trefoil peptide is the utter bee's knees for oral mucositis and inflammatory bowel disease. I was long a couple of years ago and bailed out because the company was mired in inanition and inaction. Perhaps you could tell me....have things there improv[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Honor Roll post. Vital points and good data. Things I did not know that I did not know.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
I agree with you Roger. Many conservative cardiologists argue, wisely I feel, that with aggressive lipid reduction, gradual rehab and return to fitness, complete tobacco avoidance, and good BP control, that CAD can behave like a very benign entity. I don't[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
$IBB on uptrend beginning in early 2016. We are basing for an upturn.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
https://twitter.com/pawcio2009/status/933077360630366208[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Comical[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Good morning all! NSFW: https://www.thesun.co.uk/living/4042331/mans-testicles-swell-ten-times-normal-size-sex/[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Back to my coverage of the Torrey Hills conference, I suspect that many readers of this publication are interested in cannabis plays and may be shopping around for them. I'm agnostic about marijuana. I've never tried it myself but in no way have disdain fo[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Ardelyx once interested me, but Cleveland saved our collective backside as the quants were unsound. And that appears to have infected the company's clinical programs. https://www.fiercebiotech.com/biotech/toxicity-knocks-ardelyx-hyperkalemia-hopes-back-to-[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
This is for ajgormican, to whom I'd promised to get back regarding his thoughtful query about $IMMU yesterday. I wanted to mull this one carefully. Sogiam found an older comment I posted about the company. Glenn Newberry and I had eyeballed years back; I [...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
A physician's office should be the safest place in the world for a person to disclose that she or he is something other than heterosexual. And yet it isn't: https://www.npr.org/sections/health-shots/2017/11/21/563876740/here-it-goes-coming-out-to-your-doct[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Too vague, Tumors embed themselves in a matrix of hyaluronan. Hyaluronan dampens the immune system and blocks access of chemo drugs to the tumor. Digestion of the matrix prior to treatment appears roughly to double the effectiveness of cancer treatmen[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Definitely worth reading https://forbetterscience.com/2017/11/21/anil-sood-and-how-much-md-anderson-doesnt-care-whistleblowers-speak-out/[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
Honor Roll Post. Good reading, folks.[...]
On "Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA"
I know who it is, where they live, and their IP address. Libel, lies and slander are illegal. I genuinely hope they enjoy what's about to happen to them. I also know three companies planning to sue.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.